List of publications using BEZ 235 (Axon 1281) purchased from Axon Medchem 

(total 33 publication citations listed from 2009 to AUGUST- 2017)

Muranen, T., Iwanicki, M. P., Curry, N. L., Hwang, J., DuBois, C. D., Coloff, J. L., ... & Kalaany, N. Y. (2017). Starved epithelial cells uptake extracellular matrix for survival. Nature communications, 8, 13989.

Otani, R., Mukasa, A., Shin, M., Omata, M., Takayanagi, S., Tanaka, S., ... & Saito, N. (2017). Brachyury gene copy number gain and activation of the PI3K/Akt pathway: association with upregulation of oncogenic Brachyury expression in skull base chordoma. Journal of Neurosurgery, 1-10.

Albeck, J. G., Hung, Y. P., Teragawa, C., Pargett, M., Gillies, T. E., Minguet, M., ... & Yellen, G. (2017). Akt regulation of glycolysis mediates bioenergetic stability in epithelial cells. bioRxiv, 126771.
(BEZ235, BMK120, GDC0941 and Gefitinib from Axon Medchem)

Muranen, T., Selfors, L. M., Hwang, J., Gallegos, L. L., Coloff, J. L., Thoreen, C. C., ... & Brugge, J. S. (2016). ERK and p38 MAPK Activities Determine Sensitivity to PI3K/mTOR Inhibition via Regulation of MYC and YAP. Cancer research, 76(24), 7168-7180.

Bhatia, D. R., & Thiagarajan, P. (2016). Combination effects of sorafenib with PI3K inhibitors under hypoxia in colorectal cancer. Hypoxia, 4, 163.

Mediani, L., Gibellini, F., Bertacchini, J., Frasson, C., Bosco, R., Accordi, B., ... & Sgarbi, G. (2016). Reversal of the glycolytic phenotype of primary effusion lymphoma cells by combined targeting of cellular metabolism and PI3K/Akt/mTOR signaling. Oncotarget, 7(5), 5521.

Kim, Min-Jung, et al. "Dual-Blocking of PI3K and mTOR Improves Chemotherapeutic Effects on SW620 Human Colorectal Cancer Stem Cells by Inducing Differentiation." Journal of Korean medical science 31.3 (2016): 360-370. 

de Oliveira, Antonio CP, et al. "Poly (I: C) increases the expression of mPGES-1 and COX-2 in rat primary microglia." Journal of neuroinflammation 13.1 (2016): 11. 
Jalota-Badhwar, Archana, et al. "P7170: A Novel Molecule with Unique Profile of mTORC1/C2 and Activin Receptor-like Kinase 1 Inhibition Leading to Antitumor and Antiangiogenic Activity." Molecular cancer therapeutics 14.5 (2015): 1095-1106.
*BEZ235 and AZD8055 are from Axon Medchem. 
Costales, Abran Q., et al. "Compounds and compositions as protein kinase inhibitors." U.S. Patent No. 8,859,548. 14 Oct. 2014.
*PD0325901, PD184352, SL327, LY294002, PI103, PIK75, PIK90, GDC0941, BEX235, AS252424, TGX221 are from Axon Medchem 
Schuler, Walter, Frank P. Stegmeier, and Markus Warmuth. "Use of a PKC inhibitor." U.S. Patent No. 8,748,428. 10 Jun. 2014.
* LY294002, PI103, PIK75, PIK90, AS252424, TGX221, GDC0941 are from Axon Medchem.
An ATP-competitive Mammalian Target of Rapamycin Inhibitor Reveals Rapamycin-resistant Functions of mTORC1
CC Thoreen, SA Kang, JW Chang, Q Liu, J Zhang, Y Gao, LJ Reichling, T Sim, DM Sabatini, NS Gray.
J. Biol. Chem. 2009, 284, 8023-8032.   DOI: 10.1074/jbc.M900301200

[Citation: 338, till August 9, 2012] 

Integrative molecular profiling of triple negative breast cancers identifies amplicon drivers and potential therapeutic targets.
N Turner, MB Lambros, HM Horlings, A Pearson, R Sharpe, R Natrajan, F C Geyer, M van Kouwenhove, B Kreike, A Mackay, A Ashworth, MJ van de Vijver, JS Reis-Filho.
Oncogene, 2010, 29, 2013–202. doi:10.1038/onc.2009.489
[Citation: 63, till August 9, 2012]

Activity of the Novel Dual Phosphatidylinositol 3-Kinase/Mammalian Target of Rapamycin Inhibitor NVP-BEZ235 against T-Cell Acute Lymphoblastic Leukemia.
F Chiarini, C Grimaldi, F Ricci, PL Tazzari, C Evangelisti, A Ognibene, M Battistelli, E Falcieri, F Melchionda, A Pession, P Pagliaro, JA McCubrey, AM Martelli.
Cancer Res. 2010, 7, 8097.   doi: 10.1158/0008-5472.CAN-10-1814
[Citation: 37, till August 9, 2012]

Crosstalk Between the PI3K/mTOR and MEK/ERK Pathways Involved in the Maintenance of Self-Renewal and Tumorigenicity of Glioblastoma Stem-Like Cells.
J Sunayama,, KI Matsuda, A Sato, K Tachibana, K Suzuki, Y Narita, S Shibui, K Sakurada, T Kayama, A Tomiyama, C Kitanaka. 
STEM CELLS, 2010, 28, 1930–1939.   DOI: 10.1002/stem.521

Dual blocking of mTor and PI3K elicits a prodifferentiation effect on glioblastoma stem-like cells.
J Sunayama, A Sato, KI Matsuda, K Tachibana, K Suzuki, Y Narita, S Shibui, K Sakurada, T Kayama, A Tomiyama, C Kitanaka.
Neuro. Oncol. 2010,12 (12), 1205-1219.   DOI: 10.1093/neuonc/noq103

The Quassinoid Derivative NBT-272 Targets Both the AKT and ERK Signaling Pathways in Embryonal Tumors
D Castelletti, G Fiaschetti, V Di Dato, U Ziegler, C Kumps, K De Preter, M Zollo, F Speleman, T Shalaby, D De Martino, T Berg, A Eggert, A Arcaro, MA Grotzer.
Mol. Cancer Ther. 2010, 9, 3145.   DOI: 10.1158/1535-7163.MCT-10-0539

BacMam-Enabled LanthaScreen® Cellular Assays for PI3K/Akt Pathway Compound Profiling in Disease-Relevant Cell Backgrounds.
CB Carlson, MJ Mashock and K Bi
J. Biomol. Screen. 2010, 15 (3) 327-334.   doi: 10.1177/1087057109357788

Aberrant AKT activation drives well-differentiated liposarcoma.
A Gutierrez, EL Snyderc, A Marino-Enriquez, YX Zhang, S Sioletic, E Kozakewich, R Grebliunaite, WB Ou, E Sicinska, CP Raut, GD Demetri, AR Perez-Atayde, AJ Wagner, JA Fletcher, CDM Fletcher, AT Look.
PNAS, 2011, 108 (39), 16386-16391.    DOI: 10.1073/pnas.1106127108

Pharmacological inhibition of Akt and downstream pathways modulates the expression of COX-2 and mPGES-1 in activated microglia.
ACP de Oliveira, E Candelario-Jalil, J Langbein, L Wendeburg, HS Bhatia, JCM Schlachetzki, K Biber, BL Fiebich.
J. Neuroinflam. 2012, 9, 2.   DOI:10.1186/1742-2094-9-2

Akt and ERK Control the Proliferative Response of Mammary Epithelial Cells to the Growth Factors IGF-1 and EGF Through the Cell Cycle Inhibitor p57Kip2.
DT Worster, T Schmelzle, NL Solimini, ES Lightcap, B Millard, GB Mills, JS Brugge, JG Albeck, 
Sci. Signal. 2012, 5(214), ra19.  DOI: 10.1126/scisignal.200198

Optimal induction of myeloma cell death requires dual blockade of phosphoinositide 3-kinase and mTOR signalling and is determined by translocation subtype.
C Stengel, CW Cheung, J Quinn, K Yong, A Khwaja. - -
Leukemia, 2012, 1–10.  DOI: 10.1038/leu.2012.69

Novel zebrafish model reveals a critical role for MAPK in lymphangiogenesis
RD Fevurly, S Hasso, A Fye, SJ Fishman, J Chan.
J. Pediatric Surgery, 2012, 47 (1), 177–182. [online]

Pharmacological inhibition of Akt and downstream pathways modulates the expression of COX-2 and mPGES-1 in activated microglia.
AC de Oliveira, E Candelario-Jalil, J Langbein, L Wendeburg, HS Bhatia, JCM Schlachetzki, K Biber and BL Fiebich.
J. Neuroinflammatory. 2012, 9, 2.  [online]

Compounds and compositions as protein kinase inhibitors.
AQ Costales, S Huang, JX Jin, Z Liu, S Pecchi, D Poon, J Tellew, and Q Zhang.
U.S. Patent 8,242,260, issued August 14, 2012.

AM Madera, D Poon, and A Smith. 
U.S. Patent No. 20,130,096,149. 18 Apr. 2013.

Next‐generation RNA sequencing reveals differential expression of MYCN target genes and suggests the mTOR pathway as a promising therapy target in MYCN‐amplified neuroblastoma.
A Schramm, J Köster, T Marschall, M Martin, M Schwermer, K Fielitz, G Büchel, M Barann, D Esser, P Rosenstiel, S Rahmann, A Eggert, JH Schulte.
Int. J. Cancer 2013, 132 (3), E106-E115.
Read more:

PDK1 Signaling Towards PLK1-Myc Activation Confers Oncogenic Transformation and Tumor Initiating Cell Activation and Resistance to mTOR-targeted Therapy.
J Tan, Z Li, PL Lee, P Guan, MY Aau, ST Lee, M Feng, CZ Lim, EYJ Lee, ZN Wee, YC Lim, RKM Karuturi and Q Yu.
Cancer Discovery, Published Online July 25, 2013.
Read more:
... 60 inhibitors including BEZ235 were purchased from Axon Medchem 

Compounds and Compositions as Protein Kinase Inhibitors
US 20140011825 A1
Read more:

Transcription Activator-Like Effector Nucleases (TALENs)-Mediated Deletion Of MIR17HG In Burkitt Lymphoma Cells Decreases mTOR Pathway Activity and Increases Chemosensitivity. 
Pais, F., Lee, S., Rodic, V., Barth, M. J., Cairo, M. S., & Hermiston, M. L. (2013). 
Blood, 122(21), 243-243.
Read more:

Chondrosarcoma models: understanding chemoresistance mechanisms for use in targeted treatment 
Oosterwijk, J. G. V. (2013). 
(Doctoral dissertation, Department of Pathology, Faculty of Medicine, Leiden University Medical Center (LUMC).
Read more:

RASA1 functions in EPHB4 signaling pathway to suppress endothelial mTORC1 activity.
J Kawasaki, S Aegerter, RD Fevurly, A Mammoto, T Mammoto, M Sahin, JD Mably, SJ Fishman and J Chan.
J Clin Invest. 2014, doi:10.1172/JCI67084. 
* GDC0941 and BEZ235 from Axon Medchem

Multipoint targeting of the PI3K/mTOR pathway in mesothelioma.
S Zhou, L Liu, H Li, G Eilers, Y Kuang, S Shi, Z Yan, X Li, JM Corson, F Meng, H. Zhou, Q Sheng, JA Fletcher, WB Qu.
Br. J. Cancer (2014) 110, 2479–2488. doi:10.1038/bjc.2014.220
Read more:

(This is an incomplete list, updated in AUGUST-2017)

Please wait...